Literature DB >> 1929270

In vitro susceptibility testing procedures for fosfomycin tromethamine.

A L Barry1, P C Fuchs.   

Abstract

Fosfomycin tromethamine (previously fosfomycin trometamol) is an orally administered fosfomycin which may be used for single-dose therapy of uncomplicated urinary tract infections. Fosfomycin tromethamine, norfloxacin, and trimethoprim-sulfamethoxazole inhibited greater than 90% of 352 bacterial isolates representing 25 different species; trimethoprim and nalidixic acid had narrower spectrums of activity. Strains of Escherichia, Citrobacter, Enterobacter, and Klebsiella species were much more susceptible when glucose-6-phosphate was added to the test medium, but isolates belonging to other genera were not affected.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929270      PMCID: PMC284319          DOI: 10.1128/AAC.35.6.1235

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Monuril and modification of pathogenicity traits in resistant microorganisms.

Authors:  G Li Pira; C Pruzzo; G C Schito
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

2.  Factors influencing the activity of the trometamol salt of fosfomycin.

Authors:  D Greenwood; A Jones; A Eley
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

3.  International collaborative study on standardization of bacterial sensitivity to fosfomycin.

Authors:  J M Andrews; F Baquero; J M Beltran; E Canton; F Crokaert; M Gobernado; R Gomez-Ius; E Loza; M Navarro; T Olay
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

4.  Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults.

Authors:  F Borsa; A Leroy; J P Fillastre; M Godin; B Moulin
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

5.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

  5 in total
  17 in total

1.  In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

Authors:  M de Cueto; L López; J R Hernández; C Morillo; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Susceptibility testing quality control studies with fosfomycin tromethamine.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

3.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 4.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

5.  Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy.

Authors:  Aryun Kim; Amy Kutschke; David E Ehmann; Sara A Patey; Jared L Crandon; Elise Gorseth; Alita A Miller; Robert E McLaughlin; Christina M Blinn; April Chen; Asha S Nayar; Brian Dangel; Andy S Tsai; Michael T Rooney; Kerry E Murphy-Benenato; Ann E Eakin; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

Review 6.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

7.  Identification and characterization of new inhibitors of the Escherichia coli MurA enzyme.

Authors:  E Z Baum; D A Montenegro; L Licata; I Turchi; G C Webb; B D Foleno; K Bush
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy.

Authors:  A Estebanez; R Pascual; V Gil; F Ortiz; M Santibáñez; C Pérez Barba
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-20       Impact factor: 3.267

9.  Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine.

Authors:  A L Barry; M A Pfaller; P C Fuchs; F C Tenover; L B Reller; S D Allen; D J Hardy; E H Gerlach
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

10.  Urinary concentrations of fosfomycin after a single 3 g dose of fosfomycin to elderly nursing-home patients.

Authors:  R Janknegt; P M Hooymans; G T Fabius; M K Nohlmans-Paulssen; C Machielsen; J Boogaard-van den Born; J Rang; C A Smits; M E Willems-Thissen; A Krommenhoek
Journal:  Pharm World Sci       Date:  1994-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.